These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25729840)

  • 1. The high price of cancer drugs: enough is enough.
    Prescrire Int; 2015 Jan; 24(156):27. PubMed ID: 25729840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in availability of cancer drugs across Europe.
    Mayor S
    Lancet Oncol; 2016 Sep; 17(9):1196. PubMed ID: 27476616
    [No Abstract]   [Full Text] [Related]  

  • 3. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high price of anticancer drugs: origins, implications, barriers, solutions.
    Prasad V; De Jesús K; Mailankody S
    Nat Rev Clin Oncol; 2017 Jun; 14(6):381-390. PubMed ID: 28290490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WHO Essential Medicines Committee spotlights unaffordable drugs.
    Furlow B
    Lancet Oncol; 2021 Nov; 22(11):1503. PubMed ID: 34627500
    [No Abstract]   [Full Text] [Related]  

  • 7. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 8. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cancer drug prices in the United States: reasons and proposed solutions.
    Kantarjian H; Steensma D; Rius Sanjuan J; Elshaug A; Light D
    J Oncol Pract; 2014 Jul; 10(4):e208-11. PubMed ID: 24803662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prices & availability of common medicines at six sites in India using a standard methodology.
    Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
    Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. France's health care system.
    Dhalla IA; Thomson S
    CMAJ; 2008 Feb; 178(5):596. PubMed ID: 18299552
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of privatization of the drug distribution system on drug prices in Malaysia.
    Babar ZD; Izham MI
    Public Health; 2009 Aug; 123(8):523-33. PubMed ID: 19665741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When will the U.S. flinch at cancer drug prices?
    Vanchieri C
    J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
    [No Abstract]   [Full Text] [Related]  

  • 14. Many cancer deaths could be eliminated by greater awareness and access to latest treatments, report says.
    Hawkes N
    BMJ; 2015 Jan; 350():h223. PubMed ID: 25589377
    [No Abstract]   [Full Text] [Related]  

  • 15. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient access schemes for high-cost cancer medicines.
    Williamson S
    Lancet Oncol; 2010 Feb; 11(2):111-2. PubMed ID: 20152762
    [No Abstract]   [Full Text] [Related]  

  • 17. Soaring price of cancer drugs leads plans to new approaches.
    Sipkoff M
    Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
    [No Abstract]   [Full Text] [Related]  

  • 18. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S61-86. PubMed ID: 18097697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putting a cost on extra days given by drugs.
    Singer JW
    Pharos Alpha Omega Alpha Honor Med Soc; 2008; 71(2):44; author reply 44. PubMed ID: 18686539
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
    Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
    Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.